Ocular Therapeutix, Inc OCUL
We take great care to ensure that the data presented and summarized in this overview for OCULAR THERAPEUTIX, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OCUL
View all-
Summer Road LLC West Palm Beach, FL14.4MShares$79 Million100.0% of portfolio
-
Vr Adviser, LLC New York, NY12.8MShares$70.2 Million9.97% of portfolio
-
Deep Track Capital, LP Greenwich, CT12.7MShares$70 Million3.82% of portfolio
-
Black Rock Inc. New York, NY8.06MShares$44.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.24MShares$39.8 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.15MShares$39.3 Million0.78% of portfolio
-
Opaleye Management Inc. Boston, MA6.65MShares$36.6 Million14.73% of portfolio
-
Logos Global Management LP San Francisco, CA5.81MShares$32 Million4.93% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il5.42MShares$29.8 Million0.01% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.32MShares$29.3 Million5.1% of portfolio
Latest Institutional Activity in OCUL
Top Purchases
Top Sells
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Insider Transactions at OCUL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 01
2024
|
Nadia Waheed Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
141,666
+50.0%
|
-
|
May 23
2024
|
Pravin Dugel Director |
SELL
Open market or private sale
|
Direct |
21,626
-2.53%
|
$108,130
$5.79 P/Share
|
May 23
2024
|
Sanjay Nayak Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,274
-1.26%
|
$11,370
$5.84 P/Share
|
Feb 26
2024
|
Summer Road LLC |
BUY
Open market or private purchase
|
Indirect |
930,851
+9.78%
|
$6,515,957
$7.52 P/Share
|
Feb 22
2024
|
Sanjay Nayak Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,300
+30.81%
|
-
|
Feb 22
2024
|
Pravin Dugel Director |
BUY
Grant, award, or other acquisition
|
Direct |
854,979
+50.0%
|
-
|
Feb 05
2024
|
Philip C. Strassburger General Counsel |
BUY
Open market or private sale
|
Direct |
6,029
+3.6%
|
$24,116
$4.86 P/Share
|
Feb 05
2024
|
Christopher G White Chief Business Officer |
BUY
Open market or private sale
|
Direct |
5,910
+4.56%
|
$23,640
$4.86 P/Share
|
Feb 05
2024
|
Donald Notman Chief Financial Officer |
BUY
Open market or private sale
|
Direct |
6,212
+3.08%
|
$24,848
$4.86 P/Share
|
Feb 05
2024
|
Rabia Gurses Ozden Chief Medical Officer |
BUY
Open market or private sale
|
Direct |
6,346
+3.98%
|
$25,384
$4.86 P/Share
|
Feb 05
2024
|
Antony C. Mattessich President and CEO |
BUY
Open market or private sale
|
Direct |
19,642
+3.23%
|
$78,568
$4.86 P/Share
|
Feb 03
2024
|
Philip C. Strassburger General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
58,304
+25.82%
|
-
|
Feb 03
2024
|
Christopher G White Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,980
+23.58%
|
-
|
Feb 03
2024
|
Donald Notman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,636
+23.42%
|
-
|
Feb 03
2024
|
Rabia Gurses Ozden Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,633
+29.48%
|
-
|
Feb 03
2024
|
Antony C. Mattessich President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
180,400
+22.87%
|
-
|
Jan 31
2024
|
Antony C. Mattessich President and CEO |
SELL
Open market or private sale
|
Direct |
18,338
-4.11%
|
$73,352
$4.95 P/Share
|
Jan 31
2024
|
Christopher G White Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,147
-5.43%
|
$20,588
$4.95 P/Share
|
Jan 31
2024
|
Philip C. Strassburger General Counsel |
SELL
Open market or private sale
|
Direct |
6,831
-5.89%
|
$27,324
$4.95 P/Share
|
Jan 31
2024
|
Rabia Gurses Ozden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,764
-7.72%
|
$31,056
$4.95 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.58M shares |
---|---|
Open market or private sale | 44.1K shares |
Open market or private purchase | 2.48M shares |
Open market or private sale | 69.2K shares |
---|